Login to Your Account



Other News To Note


Friday, May 27, 2011
Peregrine Pharmaceuticals Inc., of Tustin, Calif., presented data at the 10th Annual Informa Life Sciences Recombinant Antibodies Conference in Barcelona, Spain, which showed that phosphatidylserine-targeting antibodies overcame the immunosuppression in tumors that prevents immune responses to tumor cells. Antibody treatment of tumor-bearing mice caused the differentiation of highly immunosuppressive myeloid-derived suppressor cells into functional immune cells, notably M1 macrophages and dendritic cells, the company said.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription